Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism

The goal of this randomized controlled trial is to compare letrozole alone versus letrozole plus levothyroxine for ovulation induction in infertile women with both PCOS and subclinical hypothyroidism. The main questions it aims to answer are: Is letrozole plus levothyroxine superior to letrozole alone in achieving ovulation in these patients? Does combining levothyroxine with letrozole lead to higher pregnancy and live birth rates compared to letrozole alone? Participants will be randomized into two groups: Group 1 will receive letrozole only, starting at 2.5 mg daily from day 3 to 7 of the

Trial Details

NCT ID
NCT06041204
Phase
NA
Sponsor
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Letrozole 2.5mg
  • Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet
Locations (sample)
  • Cairo, Egypt|30.06263,31.24967

Key Eligibility Criteria

  • Age between 20-40 years
  • BMI between 18-35 kg/m2
  • Meet diagnostic criteria for PCOS based on the Rotterdam consensus criteria and ESHRE/ASRM modifications (2018):
  • Oligo- and/or anovulation Clinical and/or biochemical signs of hyperandrogenism Polycystic ovaries on ultrasound

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →